Evidence map›Paper›PMID 35618341›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2022

Safety of SGLT2 Inhibitors in CKD: Walking the Fine Line.

Mirela Dobre

Registry-linked trialAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06982079 (Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06982079 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

TypeinterventionalSponsorAin Shams UniversityRan2025 to 2026Enrolled60ConditionsChronic Kidney Disease Stage 5, CKD Stage 4ArmsDapagliflozin 10 mg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mirela DobreDivision of Nephrology and Hypertension, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio.ORCID 0000-0002-9059-9998

Funding

Myocardial Fibrosis in Hypertensive Adults with and without Chronic Kidney DiseaseR01HL141846 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI DOBRE, MIRELA AURORA · 2018 to 2022
$2.0M
NHLBI NIH HHS R01 HL141846
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsGlucoseHumansHypoglycemic AgentsSodium-Glucose Transporter 2GlucoseHypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorschronic kidney diseaseSGLT2sodium-glucose transporter 2 inhibitors

Identifiers

PMID35618341
PMCPMC9269644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.